Invex Therapeutics Ltd (ASX:IXC)

Market Cap	5.64M
Revenue (ttm)	1.21M
Net Income (ttm)	114.36K
Shares Out	75.15M
EPS (ttm)	0.00
PE Ratio	49.64
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,037
Average Volume	7,202
Open	0.0790
Previous Close	0.0750
Day's Range	0.0790 - 0.0820
52-Week Range	0.0590 - 0.0900
Beta	0.22
RSI	86.24
Earnings Date	May 7, 2025

About Invex Therapeutics

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IXC

Financial Performance

In 2024, Invex Therapeutics's revenue was 1.21 million, an increase of 164.06% compared to the previous year's 459,085. Losses were -1.64 million, -78.81% less than in 2023.